Recombinant Human N-myc proto-oncogene protein(MYCN)

In Stock
Code CSB-YP015278HU
Size US$1298Purchase it in Cusabio online store
(only available for customers from the US)
Image
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.

Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity Greater than 90% as determined by SDS-PAGE.
Target Names MYCN
Uniprot No. P04198
Research Area Cancer
Alternative Names bHLHe37; Class E basic helix-loop-helix protein 37; MODED; mycn; MYCN_HUMAN; N myc; N myc proto oncogene protein; N-myc proto-oncogene protein; Neuroblastoma derived v myc avian myelocytomatosis viral related oncogene; Neuroblastoma MYC oncogene; NMYC; NMYC proto oncogene protein; ODED; Oncogene NMYC; pp65/67; V myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog; v myc avian myelocytomatosis viral related oncogene neuroblastoma derived; v myc myelocytomatosis viral related oncogene neuroblastoma derived
Species Homo sapiens (Human)
Source Yeast
Expression Region 1-464aa
Target Protein Sequence MPSCSTSTMPGMICKNPDLEFDSLQPCFYPDEDDFYFGGPDSTPPGEDIWKKFELLPTPPLSPSRGFAEHSSEPPSWVTEMLLENELWGSPAEEDAFGLGGLGGLTPNPVILQDCMWSGFSAREKLERAVSEKLQHGRGPPTAGSTAQSPGAGAASPAGRGHGGAAGAGRAGAALPAELAHPAAECVDPAVVFPFPVNKREPAPVPAAPASAPAAGPAVASGAGIAAPAGAPGVAPPRPGGRQTSGGDHKALSTSGEDTLSDSDDEDDEEEDEEEEIDVVTVEKRRSSSNTKAVTTFTITVRPKNAALGPGRAQSSELILKRCLPIHQQHNYAAPSPYVESEDAPPQKKIKSEASPRPLKSVIPPKAKSLSPRNSDSEDSERRRNHNILERQRRNDLRSSFLTLRDHVPELVKNEKAAKVVILKKATEYVHSLQAEEHQLLLEKEKLQARQQQLLKKIEHARTC
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
Mol. Weight 51.6kDa
Protein Length Full Length
Tag Info N-terminal 6xHis-tagged
Form Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting
and FAQs
Protein FAQs
Storage Condition Store at -20°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time Basically, we can dispatch the products out in 3-7 working days after receiving your orders. Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA Please contact us to get it.

Target Data

Function Positively regulates the transcription of MYCNOS in neuroblastoma cells.
Gene References into Functions
  1. TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets. PMID: 30451831
  2. This suggested that NMyc regulated survival and growth of CHP134 and BE2C neuroblastoma cells, potentially through Wnt/betacatenin signaling. Furthermore, associated proteins, NMyc and STAT interactor and dickkopf Wnt signaling pathway inhibitor 1, were demonstrated to be involved in this regulation. PMID: 29749516
  3. In this report, we present a case with Feingold Syndrome having a novel mutation in MYCN gene and discuss genetic counselling and prenatal diagnosis due to pregnancy of the patient's mother. PMID: 30204967
  4. Results demonstrated that MYCN expression was downregulated in cholangiocarcinoma (CCA) through a mechanism involving miR-5095 binding its 3'UTR. PMID: 29620172
  5. MYCN levels are regulated transcriptionally by MYCNOS-01 (an alternative transcript of MYCNOS) in rhabdomyosarcoma and neuroblastoma cells. PMID: 29466962
  6. a MycN/CIP2A-mediated cell-fate bias may reflect a possible mechanism underlying early priming of some aggressive forms of neuroblastoma. PMID: 30021854
  7. CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma. PMID: 29322842
  8. Data indicate that inter-play between MYCN and the highly tumorigenic proteins which are upregulated in the malignant IMR-32 neuroblastoma cells may be fueling their aggressive behavior. PMID: 29328367
  9. these results suggest that MYCN serves as a prognostic biomarker and therapeutic target of ACR for liver cancer stem cell in de novo Hepatocellular carcinoma. PMID: 29686061
  10. Alternative nonhomologous DNA end-joining pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation have been revealed in the process of neuroblastoma initiation in mice. PMID: 29238067
  11. High TrkA expression is one of the most powerful predictor of good prognosis in neuroblastoma and is associated with younger age, lower stage, and absence of MYCN amplification PMID: 29018959
  12. overexpression of MYCN promoted cell proliferation, and induced erythroid differentiation block and apoptosis resistance to cytotoxic agent. Knockdown of MYCN inhibited the expression of EZH2, and then activated p21 expression through removal of H3K27me3 at the p21 promoter. PMID: 29022893
  13. MAX to MYCN ratio that can account for tumour progression and clinical outcome in neuroblastoma. PMID: 29408445
  14. MYCN expression is regulated by ZAR1 in neuroblastoma. PMID: 28791558
  15. The target of miR-29b was predicted using miRanda, TargetScan and PicTar sofeware and authors also found MYCN was a direct target of miR-29b in glioma cells and miR-29b inhibited the proliferation of glioma cells via MYCN dependent way. PMID: 28423357
  16. eEF2K protects MYCN overexpressing NB cells from ND in vitro and in vivo, highlighting this kinase as a critical mediator of the adaptive response of MYCN amplified NB cells to metabolic stress. PMID: 28574509
  17. Among 30 samples of brain tumor, 14 cases revealed MYCN amplification. High-protein expression of MYCN was also observed in 43.3% of patients. There was a significant correlation between MYCN gene amplification and protein expression, interestingly five case showed discrepancy between the gene amplification and protein expression. PMID: 28453467
  18. PRMT1 has a role in regulating MYCN in neuroblastoma PMID: 27571165
  19. N-myc levels appear to be modulated by the antagonistic interactions of both miR-17, as a negative regulator, and HuD, as a positive regulator in N-myc-amplified neuroblastoma cells. PMID: 28560387
  20. We also propose a model for the stabilization mechanism in which binding to Aurora-A alters how N-Myc interacts with SCF(FbxW7) to disfavor the generation of Lys48-linked polyubiquitin chains PMID: 27837025
  21. This study provides a novel insight for miR-221 in the control of neuroblastoma cell proliferation and tumorigenesis, suggesting potentials of miR-221 as a prognosis marker and therapeutic target for patients with MYCN overexpressing neuroblastoma. PMID: 28003306
  22. N-MYC is in the downstream-regulated gene family in reprogramming cancer metabolism under hypoxia [review] PMID: 27447861
  23. SNHG1 is up-regulated by MYCN amplification and could be a potential prognostic biomarker for high-risk neuroblastoma intervention. PMID: 27517149
  24. MYCN expression is a marker indicative of likely clinical sensitivity to mTOR inhibition in neuroblastoma cells PMID: 27438153
  25. Results show that MYCN and LSD1 co-localize at NDRG1 promoter and repress its expression in neuroblastoma cells. PMID: 27894074
  26. Data indicate cross-talks between MYCN and beta-catenin signalling, which repress normal beta-catenin mediated transcriptional regulation. PMID: 27531891
  27. Data show that transcription factor activating enhancer binding protein-4 (TFAP4) is a direct transcriptional target of MYCN in neuroblastoma and that high levels of this transcription factor are associated with poor clinical outcome in this disease. PMID: 27448979
  28. data extend knowledge on roles of MCPIP1 in our model and link the protein to regulation of expression and stability of MYCN through decrease of signaling via Akt/mTOR pathway. PMID: 27935099
  29. Data show that MYCN and its regulated microRNAs acted together to repress the tumor suppressor genes. PMID: 27167114
  30. Common genetic variation predisposes to different neuroblastoma genotypes, including the likelihood of somatic MYCN-amplification. [meta-analysis] PMID: 29117357
  31. Results establish evidence that high MYCN amplification can be present in retinoblastoma with or without coding sequence mutations in the RB1 gene. PMID: 28211617
  32. The study conducted metabolic profiling of pre-malignant sympathetic ganglia and tumors derived from the TH-MYCN mouse model of neuroblastoma, that overexpresses human MYCN and compared to non-malignant ganglia from wildtype littermates. These results identify enhanced glutathione biosynthesis as a selective metabolic adaptation required for initiation of MYCN-driven neuroblastoma. PMID: 26996379
  33. Many prognostic signatures for neuroblastoma are confounded by MYCN amplification. PMID: 27599694
  34. Increasing MYCN copy number is associated with an increasingly higher rate of unfavorable clinical/biological features, with 11q aberration being an exception. Patients with MYCN gain appear to have inferior outcomes, especially in otherwise more favorable groups. PMID: 28696504
  35. miR-21 enhances chemo-resistance in tongue cancer cells via directly targeting CADM1, and an inverse correlation between miR-21 and CADM1 expression in vivo. MiR-21 overexpression is attributed to MYCN-mediated transcriptional regulation, which is also predictive for a worse prognosis in tongue cancer PMID: 27055844
  36. LMO1 is an important oncogene that promotes neuroblastoma initiation, progression, and widespread metastatic dissemination. PMID: 28867147
  37. our results identify DOT1L as a novel cofactor in N-Myc-mediated transcriptional activation of target genes and neuroblastoma oncogenesis. Furthermore, they characterize DOT1L inhibitors as novel anticancer agents against MYCN-amplified neuroblastoma. PMID: 28209620
  38. CCCTC-binding factor (CTCF) targets the binding sites within MYCN promoter to facilitate its expression in neuroblastoma (NB) cells. PMID: 26549029
  39. PAX3-FOXO1 collaborates with MYCN during early rhabdomyosarcoma (RMS) tumourigenesis to dysregulate proliferation and inhibit myogenic differentiation and cell death. PMID: 28138962
  40. The findings reveal a PLK1-Fbw7-Myc signaling circuit that underlies tumorigenesis and validate PLK1 inhibitors, alone or with Bcl2 antagonists, as potential effective therapeutics for MYC-overexpressing cancers. PMID: 27773673
  41. Results show that N-Myc overexpression leads to the development of poorly differentiated, invasive prostate cancer that is molecularly similar to human NEPC. PMID: 27728805
  42. Rac activity may be an important determinant of metastatic capability in subsets of neuroblastoma cells lacking MYCN amplification. PMID: 27224546
  43. MYCN Gene Amplification is associated with Neuroblastoma. PMID: 27513929
  44. MYCN overexpression combined with activated anaplastic lymphoma kinase (ALK) is sufficient to induce neuroblastoma (NB) in mouse sympathoadrenal cells PMID: 27707976
  45. MYCN amplification can be heterogeneous between tumor sites, during tumor progression or following treatment, challenging the notion that MYCN copy number does not change for a particular neuroblastoma. PMID: 27465929
  46. High MycN expression is associated with low radiosensitivity in neuroblastoma. PMID: 27432152
  47. applying loss-and-gain function analysis, we demonstrated that miR-34a directly targeted to MYCN to sensitize NSCLC cells to cisplatin. In addition, p53 was found to monitor the expression of miR-34a in NSCLC cells after cisplatin treatment. Therefore, the sensitivity of cisplatin in NSCLC cells was modulated via p53/miR-34a/MYCN axis. PMID: 27836543
  48. Data supports our hypothesis that a positive-feedback loop of sonic hedgehog signaling induced INSM1 through N-myc and INSM1 enhanced N-myc stability contributing to the transformation of human neuroblastoma. PMID: 26456864
  49. Data show that v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) was overexpressed in non-small cell lung cancer (NSCLC) tumor tissues and cell lines, suggesting that targeting MYCN might provide beneficial effects for the clinical therapy of NSCLC. PMID: 27449038
  50. That initial decision to deny coverage could have had untoward health implications for this child, as the identification of constitutional MYCN duplication necessitated surveillance imaging for a number of pediatric malignancies associated with MYCN PMID: 27794475
  51. N-myc protein also could bind to the promoter of pri-miR-4295 and inhibit the expression of RUNX3 in glioma cells. PMID: 26756701
  52. many of the novel findings connect directly or indirectly to regulatory pathways controlling MYCN activity, bringing the old enemy into the spotlight of our current and future targeted drug efforts PMID: 27249766
  53. Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma. PMID: 26686971
  54. Authors describe an inverse correlation between WT1 gene expression and MYCN amplification and expression in neuroblastoma tumors. PMID: 26482175
  55. The MRN complex is essential to restrain MYCN-induced replication stress during neural cell proliferation. PMID: 26068589
  56. Oncogenic MYCN re-wires its own interaction and signalling networks to repress regulators of normal cellular developmental processes, such as differentiation. PMID: 26673823
  57. the expression of MYCN, HMGA2, and DICER1 seems to be correlated to each other and the expression of the let7-genes impacted by their expression. PMID: 26858029
  58. N-Myc and activated AKT1 are sufficient to transform human prostate epithelial cells to prostate adenocarcinoma and neuroendocrine carcinoma. N-Myc is required for tumor maintenance. PMID: 27050099
  59. This study strongly suggests that AT7519 is a promising drug for the treatment of high-risk neuroblastoma patients with MYCN amplification. PMID: 26202950
  60. the MNA (MYCN amplification)subclone appears to be constraint by the tumor environment and thus less relevant for tumor behavior in aggressive tumors with a high genomic instability and many segmental aberrations PMID: 26910568
  61. SOX2, KCNMB4, FOS, GLI3 and GLI1 may be involved in the pathogenesis of neuroblastoma, with the expression of SOX2 downregulating the expression of MYCN. PMID: 26398570
  62. let-7 disruption by LIN28B, MYCN sponging, or genetic loss is a unifying mechanism of neuroblastoma development with broad implications for cancer pathogenesis PMID: 27383785
  63. Suppression of MycN in human neural crest stem cells inhibits cell growth and cell cycle progression. PMID: 26815535
  64. Data indicate that suberoylanilide hydroxamic acid (SAHA) blocked the expression of MYCN protein and, by doing so, reduced the effects mediated by this protein. PMID: 26306783
  65. Three novel genes were identified as recurrently mutated; MYCN, MYO5B and VCL, and mutations in these genes were exclusively found in malignant sympathetic paraganglioma tumors. PMID: 26650627
  66. MYCN gene amplification (MNA) is strongly associated with other clinical and biological variables in neuroblastoma. Recursive partitioning has identified subgroups of neuroblastoma patients with highly disparate rates of MNA. PMID: 26709890
  67. The results do not support our hypothesis that common germline genetic variants in the MYCN genes is associated with the risk of developing medulloblastoma. PMID: 26290144
  68. N-Myc mRNA levels significantly decreased after 24h incubation with nifurtimox in neuroblastoma cell lines. PMID: 26177922
  69. study reveals a novel role of MYCN in controlling global splicing program through regulation of splicing factors in addition to its well-known role in the transcription program in nneuroblastomas. PMID: 26683771
  70. Data suggest that the protein-coding antisense transcript (MYCNOS) functions as a regulator of neuronal MYC (MYCN) ultimately controlling MYCN transcriptional variants. PMID: 26156430
  71. Data indicate that the tumor promoting effect of ataxia-telangiectasia mutated (ATM) silencing is MYCN independent. PMID: 26053094
  72. results identified a novel mechanism by which IRES-dependent translation of MYCN is repressed by miR-375, particularly during cellular stress PMID: 25864587
  73. Dual-colored fluorescence in situ hybridization on 16 primary neuroblastomas, show that those with unbalanced gain of 17q have high MYCN expression, those with no gain have medium expression, and those with numerical gain have low expression. PMID: 26171843
  74. Results identify WDR5 as a key cofactor for N-Myc-regulated transcriptional activation and tumorigenesis and as a novel therapeutic target for MYCN-amplified neuroblastomas. PMID: 26471359
  75. ITGA4 expression enhances metastasis in MYCN low neuroblastoma. PMID: 25973900
  76. rs57244888[C] is associated with susceptibility to cutaneous basal cell carcinoma. PMID: 25855136
  77. MYCN gain is prognostically significant in Wilms tumor; the novel P44L somatic variant is likely to be an activating mutation PMID: 25749049
  78. These studies implicate PRMT5 in a novel mode of MYCN post-translational regulation. PMID: 25475372
  79. ZD55-shMYCN could downregulate phosphoinositide 3-kinase and pAkt and upregulate RKIP levels PMID: 25736927
  80. ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma PMID: 24356251
  81. functional interplay between MYCN, NCYM, and OCT4 contributes to aggressiveness of MYCN-amplified human neuroblastomas. PMID: 25880909
  82. LIN28B as an important effector of the MYCN oncogenic phenotype and underline the importance of MYCN-regulated miRNAs in establishing the MYCN-driven oncogenic process. PMID: 26123663
  83. Patients with supratentorial primitive neuroectodermal tumors harboring MYCN amplification showed unfavorable overall survival PMID: 24470553
  84. CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients PMID: 25502557
  85. Increased beta-catenin expression in human high-risk neuroblastoma tissue without MYCN amplification, is reported. PMID: 25266063
  86. This article also reviews the surgical approaches to difficult thoracic and abdominal tumors, as well as the role for minimally invasive surgery in the management of localized neuroblastoma. PMID: 25486413
  87. Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. PMID: 23539269
  88. results reveal a novel function of NCYM as a regulator of Myc-nick production in human neuroblastomas PMID: 25896758
  89. These findings indicate a new way for MYCN-amplified neuroblastoma cells to interact with the tumor environment PMID: 25964525
  90. N-Myc can promote neuroblastoma cell proliferation through up-regulation of the channel kinases TRPM6 and TRPM7 PMID: 25277194
  91. There was a significant association between the histological type of samples with MYCN gene amplification. PMID: 25231001
  92. Data identify SKP2 as a direct transcriptional target of MYCN in neuroblastoma cells. PMID: 25843293
  93. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas. PMID: 25104850
  94. analysis of genes interacting functionally with MYCN required to promote fitness of tumor cells facing oncogenic stress PMID: 25477524
  95. ASCT2 expression, which correlates with that of N-Myc and ATF4, is markedly elevated in high-stage neuroblastoma PMID: 25142020
  96. Trim32 is a positive regulator of ACD that acts against MYCN and should be considered as a tumor-suppressor candidate PMID: 25100564
  97. SUMOylation may be part of a quality-control mechanism acting on misfolded Myc proteins. PMID: 24608896
  98. Data indicate glycogen synthase kinase 3-mediated regulation of MYCN mRNA levels through p53 tumor suppressor protein. PMID: 24282277
  99. Data indicate that the fastest tumor progression was observed with the undifferentiated MYCN amplified SK-N-BE neuroblastoma cells in inoculated mice. PMID: 24603724
  100. Here we describe an alternative approach to address deregulated MYCN expression. In particular, we focus on the role of a 3' untranslated region (3'UTR) of the MYCN gene in the modulation of its mRNA fate and identification of compounds able to affect it. PMID: 24515800

Show More

Hide All

Involvement in disease Feingold syndrome 1 (FGLDS1)
Subcellular Location Nucleus
Tissue Specificity Expressed in the neuronal cells of the cerebrum, neuroblastomas and thyroid tumors (at protein level).
Database Links

HGNC: 7559

OMIM: 164280

KEGG: hsa:4613

STRING: 9606.ENSP00000281043

UniGene: Hs.25960

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1